Subscribe or Manage Preferences

Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis

Rheumatology Practice Management February 2018 Vol 6 No 1 - Drug Update
Loretta Fala, Medical Writer

Psoriasis, a chronic autoimmune disease characterized by thick, inflamed patches of skin, affects approximately 7.5 million people in the United States.1 Plaque psoriasis is the most common form of psoriasis, affecting 80% to 90% of patients with the disease.2 Plaque psoriasis is characterized by raised, red patches covered with a scaly accumulation of dead skin cells.3 Complex medical care is often required to treat the pruritus, pain, and, sometimes, bleeding of psoriatic patches.1 For some patients, psoriasis can lead to disfigurement and disability.1

Patients with psoriasis are at increased risk for psoriatic arthritis, heart disease, stroke, hypertension, type 2 diabetes, metabolic syndrome, eye disorders, and obesity, as well as for other autoimmune diseases (eg, celiac disease, Crohn’s disease), Parkinson’s disease, and kidney disease.3

Psoriasis substantially affects a patient’s quality of life and self-esteem, and can lead to social isolation.3,4 In addition, the majority of patients with psoriasis regularly experience pain and pruritus.4 Individuals with psoriasis are also at increased risk for depression, anxiety, and suicidality.5

Interleukin (IL)-17 cytokines play a role in activating inflammation in the pathogenesis of psoriasis.6,7 The IL-17 receptor A (IL-17RA) antagonists, a relatively new class of drugs in the treatment of plaque psoriasis, target the IL-17 pathway.8,9

Brodalumab Receives FDA Approval for Plaque Psoriasis

On February 15, 2017, brodalu­mab (Siliq; Valeant Pharmaceuticals), a human IL-17RA antagonist, was approved by the US Food and Drug Administration (FDA) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and whose disease had an inadequate response to or stopped responding to other systemic therapies.10,11

“Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today’s approval provides patients with another treatment option for their psoriasis. Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment,” said Julie Beitz, MD, Director of the FDA’s Office of Drug Evaluation III.11

Because of the reported risk for suicidal ideation and behavior, brodalu­mab is only available through specialty pharmacies authorized to fill prescriptions under a Risk Evaluation and Mitigation Strategy (REMS) program—the Siliq REMS Program.11,12

Mechanism of Action

Brodalumab is a human monoclonal immunoglobulin G2 antibody that is selectively binding to human IL-17RA, thereby inhibiting brodalumab’s interaction with several cytokines, including IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. The IL-17RA protein plays a key role in the binding and downstream signaling of multiple IL-17 cytokines.10,13 By blocking IL-17RA, brodalumab inhibits IL-17 cytokine–induced responses, including the release of proinflammatory cytokines and chemokines implicated in the development of plaque psoriasis.10,11

Dosing and Administration

Brodalumab 210 mg is administered as a subcutaneous injection at weeks 0, 1, and 2, followed by 210 mg every 2 weeks. The brodalumab injection is available as a 210-mg/1.5-mL solution in a single-dose prefilled syringe.10

Phase 3 Clinical Trials

The safety and efficacy of brodalumab were established in 3 randomized, double-blind, controlled phase 3 clinical trials—AMAGINE-1, -2, and -3.6,10,13 These studies included 4373 adults (mean age, 45 years) with a ≥6-month history of moderate-to-severe plaque psoriasis. Approximately 21% of patients had a history of psoriatic arthritis, 30% previously received a biologic therapy, and 12% did not respond to previous biologic therapy.6,10,13

Results from these 3 trials are shown in the Table. Up to 86% of patients receiving brodalumab showed a 75% reduction in Psoriasis Area and Severity Index (PASI) score; up to 80% showed a static Physician’s Global Assessment (sPGA) score 0 (clear) or 1 (almost clear); and up to 45% showed an sPGA score 0.6,10,13

Table

In studies 2 and 3, approximately twice as many patients receiving brodal­umab 210 mg every 2 weeks achieved a 100% reduction in PASI score compared with patients receiving ustekin­umab (Stelara).10,13 Ustekinumab is a human IL-12 and IL-23 antagonist approved by the FDA for the treatment of patients with moderate-to-severe plaque psoriasis.14 In addition, at week 12, more patients in the brodalumab 210-mg arm achieved a Psoriasis Symptom Inventory score 0 (not at all) or 1 (mild) on every item, including itch, redness, scaling, burning, stinging, cracking, flaking, and pain, than patients in the placebo group.10,13

Adverse Reactions

During the 12-week randomized induction treatment of the pooled clinical trials, the most common adverse events occurring with brodalumab at a rate of ≥1% (and higher than with placebo) included arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection-site reactions, influenza, neutropenia, and tinea infections.6,10,13 Adverse events that led to brodalumab discontinuation included neutropenia, arthralgia, and urticaria.10

As with other therapeutic proteins, immunogenicity may occur with brodal­umab. Through the 52-week treatment duration, approximately 3% of patients receiving brodalumab developed antibodies to the drug.10,13

Contraindications

Brodalumab is contraindicated in patients with Crohn’s disease.10

Drug Interactions

Brodalumab may modulate the serum levels of some cytokines. When brodalumab is initiated or discontinued in patients receiving concomitant drugs that are cytochrome (CY) P450 substrates, particularly those with a narrow therapeutic index, monitoring for effect (eg, for warfarin) or drug concentration (eg, for cyclosporine) should be considered, and dose modification of CYP450 substrate may be needed.10

Warnings and Precautions

Brodalumab was approved with a boxed warning about the potential risk for suicidal ideation and behavior, including completed suicides, associated with brodalumab. The risks and benefits in patients with a history of depression and/or suicidal ideation or behavior should be weighed carefully before prescribing the drug. Patients with suicidal thoughts and behavior should be referred to a mental health professional.10

Brodalumab may increase the risk for infections, including serious infections. If a serious infection occurs, brodalu­mab should be discontinued until the infection resolves.10

Patients should be evaluated for tuberculosis infection before starting brodalumab treatment.10

Crohn’s disease and exacerbation of Crohn’s disease were reported in clinical trials of brodalumab. Brodalumab therapy should be discontinued if Crohn’s disease is diagnosed while taking the drug.10

Live vaccines should not be administered during brodalumab treatment.10

Use in Specific Populations

No human data are available on the risks associated with brodalumab in pregnant women.10

No data are available on the presence of brodalumab in human milk, or of the drug’s effects on breastfed infants or milk production. The benefits of breastfeeding and the mother’s need for brodalumab should be weighed against any potential adverse effects on the infant from brodalumab or the mother’s underlying condition.10

No differences in safety or efficacy were observed between patients aged ≥65 years and younger patients; however, the number of older patients was insufficient to establish any potential differences in response.10

The safety and efficacy of brodalumab in pediatric patients have not been established.10

Conclusion

The FDA approval of brodalumab provides another treatment option for patients with moderate-to-severe plaque psoriasis. The dosing schedule for brodalumab and its availability as a single-use, prefilled syringe may provide appropriate patients with a convenient disease management option.

References

  1. National Psoriasis Foundation. Psoriasis and comorbid conditions issue brief. www.psoriasis.org/sites/default/files/advocacy/PsoriasisandComorbidConditionsIssueBriefonepager20140225.pdf. Accessed May 23, 2017.
  2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850.
  3. Mayo Clinic staff. Diseases and conditions: psoriasis. May 12, 2017. www.mayoclinic.org/diseases-conditions/psoriasis/home/ovc-20317577. Accessed May 22, 2017.
  4. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7:e52935.
  5. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146:891-895.
  6. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273-286.
  7. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007;9:461-467.
  8. Cosentyx (secukinumab) injection [prescribing information]. East Hanover, NJ: Novartis; January 2016.
  9. Taltz (ixekizumab) injection [prescribing information]. Indianapolis, IN: Eli Lilly; January 2017.
  10. Siliq (brodalumab) injection [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America; February 2017.
  11. US Food and Drug Administration. FDA approves new psoriasis drug. Press release. February 15, 2017. www.fda.gov/newsevents/newsroom/pressannouncements/ucm541981.htm. Accessed May 18, 2017.
  12. Siliq REMS Program. Siliq certified pharmacy network. June 15, 2017. https://siliqrems.com/SiliqUI/certificationLookup.u. Accessed September 8, 2017.
  13. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318-1328.
  14. Stelara (ustekinumab) injection [prescribing information]. Horsham, PA: Janssen Biotech; September 2016.
Related Items
Kevzara (Sarilumab), a New IL-6 Receptor Antagonist Approved for Moderately to Severely Active Rheumatoid Arthritis
Loretta Fala, Medical Writer
Rheumatology Practice Management August 2017 Vol 5 No 4 published on August 16, 2017 in Drug Update
Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis
Loretta Fala, Medical Writer
Rheumatology Practice Management December 2015 Vol 3 No 6 published on January 18, 2016 in Drug Update
Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor FDA Approved for the Treatment of Postmenopausal Women with Metastatic Breast Cancer
Lisa A. Raedler, PhD, RPh
Oncology Practice Management - October 2015, Vol 5, No 7 published on October 13, 2015 in Drug Update
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
Oncology Practice Management - September 2015, Vol 5, No 6 published on September 1, 2015 in Drug Update
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera
Lisa A. Raedler, PhD, RPh
Oncology Practice Management - June 2015, Vol 5, No 5 published on June 23, 2015 in Drug Update
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh
Oncology Practice Management - May 2015, Vol 5, No 4 published on May 14, 2015 in Drug Update
Sunitinib Associated with Higher Costs Compared with Pazopanib in Patients with RCC
Chase Doyle
Oncology Practice Management - May 2015, Vol 5, No 4 published on May 14, 2015 in Drug Update
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Loretta Fala, Medical Writer
Oncology Practice Management - April 2015, Vol 5, No 3 published on April 17, 2015 in Drug Update
Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non–Small-Cell Lung Cancer
Loretta Fala, Medical Writer
Oncology Practice Management - March 2015, Vol 5, No 2 published on March 26, 2015 in Drug Update
Nivolumab (Opdivo): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Lisa A. Raedler, PhD, RPh
Oncology Practice Management - February 2015, Vol 5, No 1 published on February 23, 2015 in Drug Update
Last modified: March 19, 2018
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search